ASCO GI2024 | 一文速览中国专家相关研究

2023-12-15 16:45:00来源：2024年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）医脉通阅读：514次

2024年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）将于当地时间1月18日-20日召开。ASCO GI是消化系统肿瘤领域的学术盛会，会议将展示该领域最具创新性的科学进展，并探讨消化系统肿瘤未来的治疗方向。我国专家有多项研究将于本届盛会亮相世界学术舞台，让我们先睹为快！

Oral Abstract Session

口头报告专场

摘要号：8

标题：Effect of laparoscopy-assisted vs open surgery on 3-year disease-free survival in patients with low rectal cancer: The LASRE randomized clinical trial.

报告人：池畔

单位：福建医科大学附属协和医院

摘要号：LBA244

标题：Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.

报告人：李印

单位：中国医学科学院肿瘤医院

摘要号：245

标题：SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).

报告人：Chih-Hung Hsu

单位：台湾大学医学院附设医院

摘要号：604

标题：Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors.

报告人：李健

单位：北京大学肿瘤医院

摘要号：722

标题：Adjuvant radiotherapy after curative resection of hepatocellular carcinoma with narrow margin (≤1 cm): A phase 2, multicenter, randomized controlled trial.

报告人：匡铭

单位：中山大学附属第一医院

Poster Session

壁报专场

摘要号：24

标题：Artificial intelligence-based model for recurrence prediction after local excision on whole slide images in T1 low rectal cancer.

报告人：Chengzhi Huang

单位：广东省人民医院

摘要Bd：C5

摘要号：25

标题：Use of micronuclei DNA from erythrocytes in early-stage colorectal cancer detection.

报告人：Xingyun Yao

单位：西湖大学生命科学学院

摘要Bd：C6

摘要号：95

标题：Fruquintinib with PD-1 inhibitors versus TAS-102 with bevacizumab in late-line mCRC: A retrospective cohort study based on propensity score matching.

报告人：李蓉蓉

单位：湖南省肿瘤医院

摘要Bd：F18

摘要号：112

标题：Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.

报告人：吴珺玮

单位：上海交通大学医学院附属瑞金医院

摘要Bd：G16

摘要号：119

标题：Initial efficacy evaluation of fruquintinib plus capecitabine versus capecitabine as maintenance treatment for metastatic colorectal cancer (mCRC): A randomized, controlled, phase Ib/II study.

报告人：李文桦

单位：复旦大学附属肿瘤医院

摘要Bd：H4

摘要号：120

标题：Trifluridine/tipiracil (TAS-102) in combination with anti-EGFR re-challenge versus TAS-102 plus anti-VEGF in patients with mCRC who experienced first-line anti-EGFR-based chemotherapy.

报告人：Ching Tso Chen

单位：国立台湾大学医学院附设医院新竹台大分院

摘要Bd：H5

摘要号：124

标题：First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.

报告人：徐瑞华

单位：中山大学肿瘤防治中心

摘要Bd：H9

摘要号：125

标题：Regorafenib plus FOLFIRI with irinotecan dose escalated according to UGT1A1 genotyping in patients with metastatic colorectal cancer.

报告人：Chao-Yuan Wang

单位：高雄医学大学附设中和纪念医院

摘要Bd：H10

摘要号：126

标题：Preliminary efficacy and safety of fruquintinib as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, randomized, open-label clinical trial (the FRONT study).

报告人：刘天舒

单位：复旦大学附属中山医院

摘要Bd：C5

摘要号：131

标题：Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.

报告人：刘月

单位：浙江大学医学院附属第二医院

摘要Bd：H16

摘要号：139

标题：Fruquintinib with PD-1 inhibitors versus fruquintinib monotherapy in late-line mCRC: A retrospective cohort study based on propensity score matching.

报告人：Tianqi An

单位：郑州大学第一附属医院

摘要Bd：H16

摘要号：147

标题：Results of a prospective phase II study of total neoadjuvant therapy for locally advanced rectal cancer.

报告人：Huiying Ma

单位：中国医学科学院肿瘤医院

摘要Bd：J13

摘要号：149

标题：Consistency and heterogeneity of microsatellite instability (MSI) status in paired biopsy and surgical specimens of colorectal cancer: A necessity for MSI reassessment after treatment?

报告人：Yuan Tang

单位：四川大学华西医院

摘要Bd：J15

摘要号：156

标题：Comprehensive genomic analysis of molecular residual disease based on circulating tumor DNA in patients with postoperative colorectal cancer.

报告人：Qingqi Hong

单位：四川大学华西医院

摘要Bd：K4

摘要号：178

标题：The mechanistic study of cancer-associated adipocytes promoting colorectal cancer peritoneal metastasis via FKBP5/UCP1-mediated lipid metabolism reprogramming.

报告人：Yue Zhang

单位：广东省人民医院

摘要Bd：L6

摘要号：192

标题：Incidence and genomic characteristics of gene fusions in a large Chinese colorectal cancer cohort.

报告人：寇芙蓉

单位：北京大学肿瘤医院

摘要Bd：L20

摘要号：263

标题：Prediction of lymph node status in stage T1 esophageal squamous cell carcinoma.

报告人：Yongshun Chen

单位：武汉大学人民医院

摘要Bd：C1

摘要号：279

标题：Comprehensive molecular characteristics of clinical responses to PD-1 inhibitors plus anti-angiogenic agents (PA) in metastatic HER2-negative gastric adenocarcinoma.

报告人：Jingyuan Wang

单位：复旦大学附属中山医院

摘要Bd：C17

摘要号：281

标题：Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer with peritoneal metastasis.

报告人：Huayuan Liang

单位：南方医科大学南方医院

摘要Bd：D1

摘要号：312

标题：Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+ locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.

报告人：彭智

单位：北京大学肿瘤医院

摘要Bd：E12

摘要号：317

标题：A phase Ib/II study of ASKB589 (anti-Claudin 18.2 [CLDN18.2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma.

报告人：彭智

单位：北京大学肿瘤医院

摘要Bd：E17

摘要号：318

标题：First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.

报告人：沈琳

单位：北京大学肿瘤医院

摘要Bd：E18

摘要号：320

标题：Adjuvant chemoradiotherapy (CRT) plus pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC) with high risk of recurrence after neoadjuvant CRT plus surgery: A single-arm phase II study.

报告人：Jhe-Cyuan Guo

单位：国立台湾大学医学院癌医中心医院

摘要Bd：E20

摘要号：323

标题：A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.

报告人：Ningning Li

单位：北京协和医院

摘要Bd：F3

摘要号：327

标题：Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial.

报告人：Xiaoting Ma

单位：中国医学科学院肿瘤医院

摘要Bd：F7

摘要号：332

标题：Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single‑arm, prospective study.

报告人：Min Jin

单位：华中科技大学同济医学院附属协和医院

摘要Bd：F12

摘要号：335

标题：A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

报告人：孟祥瑞

单位：郑州大学第一附属医院

摘要Bd：F15

摘要号：337

标题：Infusional fluorouracil and weekly docetaxel as first-line therapy for gastric cancer with bone marrow metastasis and disseminated intravascular coagulation: A multi-center, phase II trial (Zhen Long).

报告人：肖健

单位：广东省人民医院

摘要Bd：F17

摘要号：340

标题：Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.

报告人：Zhiwei Chan

单位：郑州大学第一附属医院

摘要Bd：F20

摘要号：347

标题：Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).

报告人：Changying Guo

单位：江西省肿瘤医院

摘要Bd：G8

摘要号：349

标题：Neoadjuvant toripalimab plus CapeOX in patients with localized dMMR/MSI-H gastric or esophagogastric junction adenocarcinoma (GC/EGJC): Results from the cohort C of phase II NICE trial.

报告人：Liying Zhao

单位：南方医科大学南方医院

摘要Bd：G10

摘要号：351

标题：Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein–producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.

报告人：Yakun Wang

单位：北京大学肿瘤医院

摘要Bd：G12

摘要号：352

标题：Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.

报告人：yueyun chen

单位：四川大学华西医院

摘要Bd：G13

摘要号：353

标题：Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.

报告人：Ting Han

单位：上海交通大学医学院附属仁济医院

摘要Bd：G14

摘要号：354

标题：HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.

报告人：李进

单位：同济大学附属东方医院

摘要Bd：G15

摘要号：358

标题：Surufatinib plus sintilimab in patients with advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, single-center phase II trial.

报告人：Dong-Sheng Zhang

单位：中山大学肿瘤防治中心

摘要Bd：G19

摘要号：364

标题：Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.

报告人：孟祥瑞

单位：郑州大学第一附属医院

摘要Bd：H6

摘要号：371

标题：Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, open-label study.

报告人：Ruinuo Jia

单位：河南科技大学第一附属医院

摘要Bd：H13

摘要号：379

标题：Genomic analysis of oesophageal carcinoma (EC) to identify recurrent mutations in histone methyltransferases as a distinctive subset.

报告人：Jingyuan Wang

单位：复旦大学附属中山医院

摘要Bd：J2

摘要号：469

标题：Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

报告人：Feng Wen

单位：四川大学华西医院

摘要Bd：B14

摘要号：473

标题：Tinengotinib (TT-00420) in combination with atezolizumab in Chinese patients (pts) with biliary tract carcinoma (BTC): Preliminary efficacy and safety results from a phase Ib/II study.

报告人：Panpan Zhang

单位：北京大学肿瘤医院

摘要Bd：B18

摘要号：478

标题：The efficacy and safety of transarterial chemoembolization combined with cadonilimab and lenvatinib for unresectable hepatocellular carcinoma: A phase II clinical trial.

报告人：邵国良

单位：浙江省肿瘤医院

摘要Bd：C3

摘要号：486

标题：Efficacy and safety of surufatinib in biliary tract cancer: Preliminary results of a real-world study.

报告人：Zongli Zhang

单位：山东大学齐鲁医院

摘要Bd：C11

摘要号：488

标题：A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): A primary analysis.

报告人：樊嘉

单位：复旦大学附属中山医院

摘要Bd：C13

摘要号：489

标题：Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.

报告人：Miao Wang

单位：复旦大学附属肿瘤医院

摘要Bd：C14

摘要号：494

标题：Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.

报告人：Xianhai Mao

单位：湖南省人民医院

摘要Bd：D1

摘要号：498

标题：Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.

报告人：Shui-Ling Jin

单位：郑州大学第一附属医院

摘要Bd：D5

摘要号：499

标题：Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.

报告人：邵国良

单位：浙江省肿瘤医院

摘要Bd：D6

摘要号：500

标题：Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.

报告人：Yongkang Xu

单位：南昌大学第二附属医院

摘要Bd：D7

摘要号：503

标题：Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase 2 trial.

报告人：Jia-Yi Wu

单位：福建省人民医院

摘要Bd：D10

摘要号：504

标题：The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with unresectable biliary tract cancers (BTCs).

报告人：Zhifang Li

单位：中国人民解放军总医院

摘要Bd：D11

摘要号：505

标题：Adjuvant TACE plus lenvatinib as compared with TACE alone in patients with hepatocellular carcinoma at high risk of recurrence after surgery: A prospective controlled study.

报告人：Bin Zhang

单位：浙江大学医学院附属邵逸夫医院

摘要Bd：D12

摘要号：513

标题：Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery: A single arm, multi-center, phase II clinical trial.

报告人：Zheng Wu

单位：西安交通大学第一附属医院

摘要Bd：D20

摘要号：517

标题：Neo-adjuvant tislelizumab combined with lenvatinib treatment for resectable, recurrent hepatocellular carcinoma.

报告人：匡铭

单位：中山大学附属第一医院

摘要Bd：E4

摘要号：530

标题：Prognostic value of minimal residual disease profiling in resectable hepatocellular carcinoma.

报告人：Jie Hu

单位：复旦大学附属中山医院

摘要Bd：E17

摘要号：556

标题：Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma.

报告人：Yun-Fan Sun

单位：复旦大学附属中山医院

摘要Bd：G4

摘要号：625

标题：Predictive machine learning models for survival outcomes in patients with pancreatic cancer.

报告人：Yang-Chen Shen

单位：国立成功大学医学院

摘要Bd：J12

摘要号：648

标题：A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.

报告人：Yan-Shen Shan

单位：国立成功大学医学院

摘要Bd：K17

摘要号：653

标题：Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.

报告人：吴珺玮

单位：上海交通大学医学院附属瑞金医院

摘要Bd：L2

摘要号：658

标题：The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with metastatic pancreatic cancer (mPC).

报告人：Meixia Chen

单位：中国人民解放军总医院

摘要Bd：L7

摘要号：659

标题：Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).

报告人：张东生

单位：中山大学肿瘤防治中心

摘要Bd：L8

摘要号：671

标题：Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).

报告人：Ru Jia

单位：解放军总医院第五医学中心

摘要Bd：L20

摘要号：729

标题：Unveiling prognosis and traits of dMMR/MSI-H gastric and colorectal cancer after curative surgery: A large-scale, multi-center, retrospective study in China.

报告人：Ting Deng

单位：天津医科大学肿瘤医院

摘要Bd：L4

摘要号：735

标题：Liquid biopsy-based comprehensive genomic profiling to reveal mutational landscape in real-world patients with gastrointestinal cancer.

报告人：Haoran Tang

单位：Huidu Shanghai Medical Sciences, Ltd.

摘要Bd：L10

摘要号：738

标题：Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.

报告人：Yujia Zhu

单位：中山大学肿瘤防治中心

摘要Bd：L13

摘要号：739

标题：Multicenter clinical validation of GutSeer: A cost-effective, blood-based assay for early detection and localization of major gastrointestinal cancers.

报告人：Wanqing Chen

单位：中国医学科学院肿瘤医院

摘要Bd：L14

摘要号：754

标题：Is lymph node metastasis an event indicating an advanced gastrointestinal stromal tumor?

报告人：Peng Zhang

单位：华中科技大学同济医学院附属协和医院

摘要Bd：M9

Trials in Progress Poster Session

进行中的试验海报专场

摘要号：TPS225

标题：A randomized controlled trial of CAPEOX vs observation in patients with early-stage colorectal cancer with positive MRD after curative surgery (CAREME).

报告人：丁克峰

单位：浙江大学医学院附属第二医院

摘要Bd：N13

摘要号：TPS233

标题：Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab for locally advanced MSS of middle and low rectal cancer (mRCAT): An open-label, single-arm, prospective, multicentre clinical trial.

报告人：宋章法

单位：浙江大学医学院附属邵逸夫医院

摘要Bd：P1

摘要号：TPS415

标题：Prospective assessment of adenocarcinoma of esophagogastric junction (AEG) following radical resection: Real-world insights from the CLAEG study.

报告人：Jiabin Zheng

单位：广东省人民医院

摘要Bd：M20

摘要号：TPS426

标题：A modified triplet combination of docetaxel, oxaliplatin, and fluorouracil for gastric cancer (GC) with peritoneal carcinomatosis (PC) and inoperable malignant bowel obstruction (MBO): A multi-center, non-randomized, three-cohort, phase II trial (Zhen Jing).

报告人：肖健

单位：广东省人民医院

摘要Bd：N11

摘要号：TPS427

标题：A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.

报告人：沈琳

单位：北京大学肿瘤医院

摘要Bd：N12

摘要号：TPS428

标题：Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer.

报告人：梁寒

单位：天津医科大学肿瘤医院

摘要Bd：N13

摘要号：TPS579

标题：Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.

报告人：Gong-Rang Chen

单位：益阳市中心医院

摘要Bd：P8

摘要号：TPS582

标题： phase II study to evaluate the safety and efficacy of anlotinib combined with penpulimab for advanced refractory biliary tract cancer.

报告人：Xiaojun He

单位：空军医科大学附属第二医院/唐都医院

摘要Bd：P11

备注：排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~